Status:
UNKNOWN
Study of Endothelial Dysfunction in Systemic Lupus and Its Role in Heart Disease
Lead Sponsor:
University Health Network, Toronto
Collaborating Sponsors:
Heart and Stroke Foundation of Canada
Conditions:
Systemic Lupus Erythematosus
Eligibility:
All Genders
20+ years
Phase:
PHASE4
Brief Summary
Systemic Lupus Erythematosus is a relatively common autoimmune disease that affects mainly women.Cardiovascular disease as a result of accelerated atherosclerosis is a major cause of mortality and mor...
Eligibility Criteria
Inclusion
- \>20 years Lupus according to ACR criteria Patients who demonstrate abnormality on mycardial perfusion imaging are eligible for treatment arm of study
- \-
Exclusion
- Steroid dependent asthma known contraindication to dipyridamole known intolerance to or contraindication to use of ACE inhibitors history of angioedema serum creatinine. 200mmol/l Renal artery stenosis pregnant or breast feeding inability to perform low grade exercise presently taking ACE, ARB or nitrates
Key Trial Info
Start Date :
March 1 2002
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00188188
Start Date
March 1 2002
Last Update
December 29 2005
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Health Network, Toronto Western Division
Toronto, Ontario, Canada, M5T 2S8